Earnings ·
Olema Pharmaceuticals reported second quarter 2026 financial results ending June 30, 2026
OLMAOlema Pharmaceuticals, Inc.
Olema Pharmaceuticals reported second quarter 2026 financial results ending June 30, 2026. The company ended the quarter with $461.1 million in cash, cash equivalents, and marketable securities. Net loss for the period was $63.2 million, compared to a net loss of $43.8 million in the prior year period. Research and development expenses increased to $57.8 million from $43.9 million, driven by higher clinical development spending on palazestrant and OP-3136. General and administrative expenses rose to $9.4 million from $4.0 million due to increased corporate infrastructure costs. Clinically, Olema completed enrollment in the pivotal Phase 3 OPERA-01 trial for palazestrant, with top-line data expected in the first quarter of 2027. The company also announced a clinical collaboration with Bayer to evaluate OP-3136 in combination with darolutamide for metastatic castration-resistant prostate cancer and presented initial Phase 1 monotherapy data for OP-3136 at ASCO. Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer.